Nordic Nanovector has unveiled updated results from its LYMRIT 37-01 Phase l/ll clinical trial of Betalutin (177Lu-satetraxetan-lilotomab) to treat patients with relapsed/refractory (R/R) indolent NHL (iNHL) and third-line follicular lymphoma (3L FL).
The updated data showed that single-agent of Betalutin has been able to reduce the tumour size of 90% of the patients (59) enrolled in the study.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial has witnessed 60% overall response rate (ORR) and 24% complete response (CR) for all evaluable iNHL patients.
Betalutin was also found to be highly active in patients with two or more prior therapies including 3L FL with 66% ORR and 25% CR.
In addition, the treatment was well-tolerated with a safety profile characterised by reversible transient neutropenia and thrombocytopenia, as well as a low number of infections.
LYMRIT 37-01 Phase l/ll study principal investigator Dr Arne Kolstad said: “The combination of efficacy, tolerability and the convenience of a single administration highlight Betalutin’s potential in this primarily elderly, heavily pre-treated patient population.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Notably, the CRs seen in both arm one and arm four in FL patients and the duration of responses are very promising, and we look forward to treating more patients in the upcoming PARADIGME study.”
The new Phase l/ll study data is expected to help Nordic to conduct the Phase llb PARADIGME trial for relapsed/refractory (R/R) indolent NHL (iNHL) and FL diseases.
Currently, Nordic Nanovector is engaged in the development of new therapies to address major unmet medical needs and advance cancer care.
